Blood/hematologic cancers most often begin in the bone marrow where blood is produced. Stem cells in the bone marrow develop into white blood cells, red blood cells, or platelets. Blood cancers occur when uncontrolled growth of abnormal blood cells overtakes the development of normal blood cells and interferes with the regular functions of these cells. Blood cancers fall into three categories: leukemia, lymphoma, and myeloma.
Leukemias are blood cell cancers; some leukemias are fast growing, while others develop slowly. Most often leukemia is diagnosed in adults over the age of 55, but it is also a commonly seen in children under the age of 15. For 2018, the American Cancer Society estimates the U.S. will see about 60,300 new cases of leukemia (all kinds) and 24,370 deaths from leukemia (all kinds).
Lymphoma occurs when lymphocytes (infection-fighting white blood cells) develop abnormally and become lymphoma cells. These multiply and aggregate in lymph nodes and other tissues. Among common lymphomas are Hodgkin lymphoma, non-Hodgkin Lymphoma, AIDS-related lymphoma, and primary central nervous system (CNS) lymphoma. In 2018, about 83,180 new cases of lymphoma are expected to be diagnosed in the U.S. (8,500 cases of Hodgkin lymphoma; 74,680 cases of non-Hodgkin lymphoma).
Myeloma is a cancer that occurs in plasma cells. Normal plasma cells create antibodies that fight disease and infection. However, when abnormal myeloma cells develop, they interfere with the antibody production and lead to lessened immunity. An estimated 30,770 new cases of multiple myeloma will be diagnosed in the U.S. in 2018.
Sources: American Cancer Society; American Society of Hematology; Leukemia & Lymphoma Society; National Cancer Institute.
Clinical updates on MRD testing for Chronic Lymphocytic Leukemia (CLL) and the importance of incorporating it into the treatment plan.
ACCC is hosting a webinar with expert faculty in the field of hematologic malignancies. Gain important and practical information for the assessment of measurable residual disease (MRD) as part of routine clinical practice for their patients with chronic lymphocytic leukemia (CLL).
The presentation will be valuable for understanding the impact of MRD on treatment decisions and practice patterns, which has promise to lead to major improvements in outcomes for CLL patients in the very near future.
ACCC is committed to help ensure access to recommended care for patients who receive treatment for multiple myeloma or acute lymphoblastic leukemia through a partnership with the American Cancer Society and Project ECHO. The educational focus will be on bringing the latest content knowledge and best practices in the treatment of these hematological cancer patients to your cancer care team.
Participation in the TeleECHO Clinic is free. The clinics will convene by videoconference each month.
B-cell Acute Lymphoblastic Leukemia (ALL) was the first disease state with an FDA-approved treatment for MRD. This project will help lay the foundation for MRD testing in patients with B-cell ALL to create better-informed multidisciplinary cancer care teams. Ultimately, this work will showcase not only the importance of MRD testing, but also how it can be best integrated into the cancer care workflow.
The ACCC Multidisciplinary Acute Lymphocytic Leukemia (ALL) Care education project seeks to identify key barriers to and opportunities for improvement in the cancer care team’s support of patients diagnosed with ALL, including utilization of MRD testing, detection, and monitoring.
Read ACCC’s environmental scan including an overview of the current landscape for ALL diagnosis and treatment, along with opportunities to improve patient care.
The ACCC Multidisciplinary Chronic Lymphocytic Leukemia (CLL) Care education project seeks to understand the current landscape of treating CLL in the community, identify effective practices and potential gaps in provider and patient communication, and provide peer-to-peer learning and resources for increased awareness and best practices in multidisciplinary care for patients with CLL.
Guided by an expert Advisory Committee, this ACCC education project provides support to multidisciplinary cancer care teams in diagnosing, testing, and treating patients with multiple myeloma. This project serves to:
The ACCC education project, The Transplant Treatment Path: Optimizing Patient-Centered Care for ASCT in Multiple Myeloma, explores steps for improving provider communication to optimize the treatment of multiple myeloma patients in the community cancer center pre- and post-autologous stem cell transplant (ASCT).